Roivant Sciences Ltd. (ROIV) and its subsidiary Genevant Sciences, together with partner Arbutus Biopharma, reached a $2.25 billion global settlement with Moderna Inc. The agreement, announced on March 3, 2026, resolves all U.S. and international enforcement actions stemming from Moderna’s use of Genevant’s lipid‑nanoparticle (LNP) technology in its COVID‑19 and RSV vaccines.
The settlement structure includes an upfront payment of $950 million payable in July 2026, of which Roivant is expected to receive roughly 60‑70 percent. A contingent payment of $1.3 billion will be triggered if an appellate ruling upholds the patents, specifically if Moderna’s appeal of Section 1498 of U.S. law is unsuccessful.
Genevant granted Moderna a global non‑exclusive license to its LNP delivery platform for infectious‑disease applications, ensuring that Moderna can continue to use the technology without further litigation while retaining the right to license the platform to other parties.
For Roivant, the cash inflow is a significant, non‑dilutive boost that validates the core intellectual property underpinning its broader strategy of leveraging nucleic‑acid delivery platforms. The proceeds are earmarked to support ongoing clinical development and could reduce the need for future equity financing, thereby preserving shareholder value and potentially expanding the company’s share‑buyback program.
Moderna will record a $950 million charge in the first quarter of 2026, but the company projects a strong cash position of $4.5 billion to $5 billion at the end of 2026. The settlement removes a major legal overhang, allowing Moderna to focus on its near‑term growth plans, including a return to revenue growth in 2026 and breakeven by 2028.
Investors and analysts have welcomed the settlement, noting that the removal of a long‑standing legal risk and the favorable terms provide clarity for both companies. The agreement is viewed as a positive development for Moderna’s financial stability and for Roivant’s pipeline investment strategy.
The dispute over LNP technology predates the COVID‑19 pandemic, with Genevant and Arbutus filing the initial lawsuit in February 2022. The settlement is part of a broader landscape of patent disputes involving LNP technology, and the Section 1498 appeal is a critical legal question that could shift liability to U.S. taxpayers. By resolving this matter, both parties secure a clearer path forward in the rapidly evolving mRNA vaccine market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.